BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jauregui-Amezaga A, Vermeire S, Prenen H. Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. Ann Gastroenterol 2016;29:127-36. [PMID: 27065724 DOI: 10.20524/aog.2016.0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Herrera-Gómez RG, Grecea M, Gallois C, Boige V, Pautier P, Pistilli B, Planchard D, Malka D, Ducreux M, Mir O. Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease. Cancers (Basel) 2022;14:2914. [PMID: 35740579 DOI: 10.3390/cancers14122914] [Reference Citation Analysis]
2 Albishi AM, Chakik R, Bazeed M. Renal Cell Carcinoma in Fistulizing Crohn's Disease Patient Who Received Anti-TNF α Therapy. Case Rep Gastrointest Med 2021;2021:5593067. [PMID: 33968453 DOI: 10.1155/2021/5593067] [Reference Citation Analysis]
3 Weimers P, Ankersen DV, Løkkegaard ECL, Burisch J, Munkholm P. Occurrence of Colorectal Cancer and the Influence of Medical Treatment in Patients With Inflammatory Bowel Disease: A Danish Nationwide Cohort Study, 1997 to 2015. Inflamm Bowel Dis 2021:izaa340. [PMID: 33409534 DOI: 10.1093/ibd/izaa340] [Reference Citation Analysis]
4 Morvillo C, Vinci K, Hedenschoug L, Mancini L, Mize C, Tugg K, Stein S. Risks and Safety of Advanced Therapies and Biologics in Inflammatory Bowel Disease: A Review for Nurses. Gastroenterology Nursing 2020;43:E159-71. [DOI: 10.1097/sga.0000000000000523] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Restellini S, Chazouillères O, Frossard JL. Hepatic manifestations of inflammatory bowel diseases. Liver Int 2017;37:475-89. [PMID: 27712010 DOI: 10.1111/liv.13265] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]